###### Strengths and limitations of this study

-   To the best of our knowledge, no published systematic review addresses delayed diagnosis and initiation of tuberculosis (TB) treatment in high-burden countries.

-   This study will review and triangulate qualitative and quantitative findings to provide a more comprehensive and holistic view on the matter.

-   We anticipate that this review might not be represented by all 30 countries in the high TB burden list due to the lack of evidence and research activities in a few countries.

-   Another possible limitation may be the heterogeneity of the studies exploring the factors associated with delayed diagnosis and treatment of TB.

Introduction {#s1}
============

Tuberculosis (TB) is a leading infectious cause of morbidity and mortality worldwide, accounting for 10 million new cases and 1.6 million deaths in 2017.[@R1] The disease burden is disproportionately concentrated in low-income and middle-income countries, with over 95% TB deaths contributed by these regions.[@R1] Many of these deaths are preventable through early diagnosis and treatment, yet, in 2017, nearly 40% of TB cases remained undiagnosed globally.[@R1] Limited access to healthcare, high treatment cost and the social stigma of TB have contributed to delayed detection and poor treatment uptake.[@R3] Other risk factors such as poor living conditions and overcrowding further perpetuate the transmission of TB and infection, which, in turn, leads to social and economic insecurity.[@R5] The financial burden of TB attributed by the loss of income, logistics and medical expenditures is high, with the total costs incurred amounting to 58% and 39% of reported annual individuals and household income, respectively.[@R6]

Traditionally, TB cases are captured and passively notified when people with TB present themselves to a health facility. In recent years, a more proactive strategy to increase TB case detection, namely active case finding (ACF) has gained traction and is reported to be effective in promptly identifying people with TB.[@R7] Alongside passive case finding, the ACF strategy has been adopted by countries affected by the epidemic to reach people with TB effectively.[@R8] Nevertheless, despite increased efforts to improve case detection, TB case finding remains a great challenge due to limited resources, geographical barriers and social stigma.[@R10] Delays in TB diagnosis and care will increase the prevalence of infectious TB, perpetuates greater transmission and ultimately impedes the global efforts to eliminate TB by 2030.[@R13]

Delays in diagnosis and detection have been identified as one of the key challenges to eliminate TB.[@R15] A review of the literature found several published systematic reviews on factors associated with delayed TB diagnosis. Two systematic reviews focused primarily on reasons for delayed TB diagnosis in India.[@R16] Two other reviews published in 2017 were specific to children and youth in sub-Saharan Africa and hard-to-reach populations such as migrants, refugees, prisoners, sex workers, people living with HIV, people who use drugs and homeless people.[@R18] Methodologically, most reviews evaluated predominantly qualitative data, and reviewers have expressed limitations in reporting summary estimates due to great heterogeneity of the studies.[@R19] One review conducted in 2008 attempted to extract findings from quantitative studies, regardless if they met the criteria for a meta-analysis.[@R21] These studies, though, were mostly conducted between the 1990s and early 2000s.[@R21] With regard to geographical regions, a recent review investigated the factors associated with delayed diagnosis in the low-income and middle-income countries but included only observational study design, and no qualitative studies were synthesised.[@R4] Also, a scoping review with a specific focus on the relationship between acceptability barrier (expectations from health providers/care process, attitudes of health providers and health beliefs) and delayed diagnosis of TB among high multidrug-resistant TB countries was recently published in 2016, but only qualitative studies were synthesised.[@R22] Collectively, there are empirical evidence to associate various factors---sociodemographic, clinical, health system, economic and political---to delay in healthcare seeking and treatment of TB. However, delays in diagnosis and treatment exist to varying degrees across countries with a different population and a different burden of the disease. To our knowledge, no published systematic review addresses delayed diagnosis and initiation of TB treatment in countries bearing most of the global TB burden. There is also a lack of review that triangulates qualitative and quantitative findings to provide a more comprehensive and holistic view on the matter.

The WHO developed the concept of high-burden countries in 1998, and it was conceptualised to focus global efforts in countries where improvement is needed to curb the epidemic. The concept has since been widely used to rally political commitments, funding and interventions in these countries.[@R23] There are currently three high-burden countries list for TB---TB, multidrug-resistant TB and TB/HIV---that are defined for 2016--2020.[@R23] Each of this list accounts for approximately 85% of the global burden in their respective domains. Hence, it is pertinent to focus efforts on these high-burden countries to end TB globally by 2035.

Objective of systematic review {#s1a}
------------------------------

This systematic review aimed to review current evidence on factors associated with delayed diagnosis and treatment of pulmonary TB in the high TB burden countries to inform the development of effective case finding and TB prevention interventions. We will focus on the delayed diagnosis of pulmonary TB regardless of the drug sensitivity or resistant status of the infecting TB pathogen.

Methods {#s2}
=======

Eligibility criteria {#s2a}
--------------------

We will consider studies that include people with TB, presumptive TB, key stakeholders involved in TB management and controls, the general and other populations that include, but not limited to, migrants and refugees, elderly, children, people living with HIV, prisoners and people with diabetes.

This review will include qualitative, observational studies (cross-sectional studies, case-control studies and cohort studies---both retrospective and prospective) conducted in the WHO high TB burden countries, namely Angola, Bangladesh, Brazil, Cambodia, Central African Republic, China, Congo, Democratic People's Republic of Korea, Democratic Republic of Congo, Ethiopia, India, Indonesia, Kenya, Lesotho, Liberia, Mozambique, Myanmar, Namibia, Nigeria, Pakistan, Papua New Guinea, the Philippines, Russian Federation, Sierra Leone, South Africa, Tanzania, Thailand, Vietnam, Zambia and Zimbabwe.

All studies that investigated factors associated with delayed TB diagnosis and initiation of treatment and published between 2008 and 2018 will be considered. These factors include demographics, socioeconomic, clinical, knowledge and attitude variables. As TB diagnosis criteria might differ from one country to another, we will regard all TB cases evaluated by a health facility that is equipped or linked to a laboratory with one of the diagnostic tools---smear microscopy, culture, GeneXpert and drug susceptibility test---and the presence of clinicians to make the final diagnosis as TB. We will exclude studies that evaluated self-reported TB cases if any. We will not impose limits on the studies by sample size. We will include the following primary outcomes---(1) patient delay: the time interval between the onset of symptoms and the first encounter with healthcare professionals; (2) health system/doctor/provider/diagnostic delay: the time interval between the first encounter with healthcare professionals and the diagnosis of pulmonary TB; (3) treatment delay: the time interval between TB diagnosis and the initiation of anti-TB treatment; and (4) total delay: the time interval between onset of symptoms and the initiation of anti-TB treatment.

We will exclude systematic reviews, meta-analyses, scoping reviews, intervention studies and non-English articles (except articles in Chinese), studies lacking key outcome data and/or unclear reporting of primary outcomes and publications in the form of letters, reviews, commentaries and editorials. The meta-analysis will only include studies with regression analysis as we will need the effect sizes of the factors associated with TB diagnosis and initiation of treatment. Relevant studies without regression analysis will only be reviewed in the narrative.

Search strategy and information sources {#s2b}
---------------------------------------

The search strategy aims to find published studies and will include three stages. First, a limited search of articles on PubMed and EMBASE, and an analysis of the index terms and keywords contained in the title and abstract will be undertaken. Appropriate free-text index terms, keywords, and Medical Subject Headings terms will be developed from the initial search. Using these identified search terms, a second search will be conducted across PubMed, EMBASE, CINAHL and PsycINFO using Boolean logic operators---AND and OR. A draft search strategy for EMBASE is appended in online [supplementary file 1](#SP1){ref-type="supplementary-material"}. Third, the reference lists of key articles, including relevant systematic reviews and meta-analyses, will be screened for additional studies. In this review, we will consider studies published in English and Chinese between 2008 and 2018, inclusive.
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Study selection {#s2c}
---------------

All identified citations will be exported into EndNote X8 (Clarivate Analytics, Philadelphia, Pennsylvania, USA) and duplicate will be removed. Subsequently, citations will be exported to Microsoft Excel Office 365 (Microsoft Corporation, Washington, DC, USA). Two independent reviewers will screen the titles and abstracts based on the inclusion criteria. Full-text articles of the selected citations will be retrieved and screened by two independent reviewers. We will exclude full-text articles that do not meet the inclusion criteria and include the reasons for these exclusions in the final review. Selected studies will be critically appraised, and data from each respective study will be extracted and synthesised. The results of the search will be presented in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guideline. We will seek the opinion of a third reviewer should any disagreements arise between the two primary reviewers.

Quality assessment {#s2d}
------------------

Selected studies will be critically assessed by two independent reviewers using the Newcastle-Ottawa Scale to assess the quality of non-randomised studies (cross-sectional studies, case-control studies and cohort studies) in meta-analyses.[@R24] We will assess qualitative studies using the Critical Appraisal Skills Programme (CASP) tool.[@R25] In addition, we will grade the final synthesised qualitative findings according to the ConQual approach to rate the level of confidence and certainty of the findings.[@R27] Synthesised findings will be presented in a Summary of Findings table, which will include information on the type of research, dependability, credibility, ConQual score and comments on the findings, if any. Grading of the dependability and credibility of synthesised findings will be done using the Joanna Briggs Institute Summary of Findings Tables.[@R28] The Summary of Findings table will also include the systematic review title, population, phenomena of interest and the context. Any disagreements will be resolved through discussion with a third reviewer.

Data extraction and management {#s2e}
------------------------------

Quantitative and qualitative data will be extracted independently by two researchers. We will develop a standardised form to record study (eg, year, study design, location and sample size) and participants\' characteristics (eg, study respondents, median/mean age, sex and the duration of delay, if available), primary outcome measures (patient delay, doctor/health system delay and treatment delay), main findings (factors associated with delays) and study quality scores. In the event where information regarding the selected studies are lacking, we will contact the respective authors and request for the information.

Data synthesis and analyses {#s2f}
---------------------------

We will report study settings, countries and sample size by study design. A narrative synthesis of the independent variables will be generated. We anticipate that there will be significant variations in the factors associated with delayed diagnosis. Howbeit, we will seek to estimate the effect of factors associated with a delayed diagnosis and treatment if data are available in two or more studies. Data will be pooled by meta-analysis using RevMan V.5 (The Cochrane Collaboration, Oxford, UK) and R (R Foundation for Statistical Computing, Vienna, Austria). We will present effect sizes as OR and their 95% CI. Levels of heterogeneity will be quantified using chi-square statistic Q and I^2^. If considerable heterogeneity will be detected, a subgroup analysis on smear status and the geographical region will be performed to assess its source. Findings will be presented in forest plot and narrative form if statistical pooling is not feasible. Publication bias will be assessed using forest plots and Egger's tests.[@R29] For qualitative studies, findings and sample quotes reported will be extracted verbatim. We will annotate and analyse the extracted data using NVIVO by QSR International. Textual references to topics of interest will be retrieved and categorised using qualitative thematic analysis. Two authors will code the data independently, and discrepancies will be discussed to standardise code definitions. We will examine codes in details for subthemes and patterns. We will synthesise these data with quantitative findings for a complete understanding of the reasons for delayed TB diagnosis and treatment. We aim to perform gender-based analyses of the factors associated with delayed diagnosis and treatment of TB and present results by geographical region that the high-burden countries represent.

Presentation and reporting of results {#s2g}
-------------------------------------

A flow chart representing each stage of the studies\' selection process will be presented as per the PRISMA guidelines. We will present factors associated with patient delay, health system/doctor/provider/diagnostic delay and treatment delay among high TB burden countries using tables and forest plots. Risk of bias scores for methodological quality of studies included in this review will be tabulated together with comments supporting the decisions.

Patient and public involvement {#s2h}
------------------------------

Patients and members of the public were not involved in the design and development of this research. The findings from this review will be published and shared in conference presentation.

Discussion {#s3}
==========

To our knowledge, this systematic review will be the first to focus on countries with a high TB burden. This protocol was developed using validated tools and processes, yet, there are several noteworthy limitations. First, we might miss studies that are relevant to this review. We strive to minimise this issue by working with a librarian on the search strategy and assessing the reference list of similar reviews that have been published. Second, we anticipate that this review might not be represented by all 30 countries in the high TB burden list due to the lack of evidence and research activities in several countries. Therefore, it may be difficult to conclude universally for all high TB burden countries.

Nevertheless, we hope that this review may highlight gaps in knowledge and provide insights into the reasons for delayed TB diagnoses in high-burden countries. These findings will also inform future research and key stakeholders in developing interventions to reach these undiagnosed cases effectively.
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